Fog Pharmaceuticals

The page describes mRNA display as a technology for discovering high-diversity peptide binders, with large libraries and tight genotype–phenotype linkage, while noting technical complexity and reliance on specialized techniques.

The company develops therapies.

Jonathan Hurov brings to Parabilis Medicines an impressive track record in oncology drug discovery and platform biology. With multiple patents, publications and extensive experience, he leads discovery biology, proteomics and biochemistry.

Kristen Stants is Parabilis Medicines’ chief people officer and leads the development, implementation, and alignment of Parabilis Medicines’ people strategy.

Marie leads Parabilis Medicines’ clinical strategy, clinical trial protocol design, medical oversight, and pipeline strategy support. Marie was an Executive Director in Early Clinical Development, Hematology/Oncology and Cell Therapy at Bristol Myers Squibb.

The company advances research and therapies for cancer and other serious diseases.

Formerly known as Fog Pharmaceuticals, Parabilis Medicines was founded in 2015 to address a fundamental gap in modern drug development: the great progress that has been made in identifying human disease targets has not been matched by advances in the ability to develop medicines for them.

The company has pioneered a new class of alpha-helical peptides – Helicons – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines.

Parabilis Medicines’ privacy policy describes its practices for protecting and managing personally identifiable information shared by visitors to its website.